Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer

(MedPage Today) — BERLIN — The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back randomized clinical trials.
In…